Baird lowered the firm’s price target on Dianthus (DNTH) to $50 from $58 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company updated it product pipeline.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics
- Dianthus Therapeutics Reports Increased R&D Expenses
- Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability
- Dianthus completes enrollment for Phase 2 MaGic Trial of DNTH103
- Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue